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 Adenosine A 2A agonists as 
therapy for glomerulonephritis 
 David A.  Ferenbach 1 and  Jeremy  Hughes 1 
 Garcia  et al. report the utility of pharmacological activation of the 
adenosine A 2A receptor (A 2A R) in preserving renal function, reversing 
fibrosis, and reducing macrophage infiltration and inflammatory 
activation in rat nephrotoxic nephritis. The role of A 2A R activation in 
determining outcome in renal inflammation is discussed. 
 Kidney International (2011)  80, 329 – 331.  doi: 10.1038/ki.2011.167 
 Although macrophage infiltration is 
impor tant in renal injury that includes 
glome rulonephritis, 1 appropriate leukocyte 
recruitment and activation are also a vital 
step in reparative tissue responses. Persistent 
tubulointerstitial and glomerular macro-
phage infi ltration is a hallmark of chronic 
infl ammatory disease and a feature of many 
progressive renal diseases. Immunosuppres-
sion may interrupt the natural history of 
renal inflammatory disease but is often 
incompletely eff ective and is associated with 
treatment-related complications. Th ere is 
much research examining the immune 
mechanisms underlying chronic infl amma-
tion and the associated inade quacy of dis-
ease resolution pathways, and it is hoped 
that identification of some of the cues 
responsible for limiting active infl ammation 
and initiating the resolution phase will lead 
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to novel targeted therapies capable of abort-
ing infl ammatory disease with an improved 
side-eff ect profi le. 
 One putative  ‘ anti-infl ammatory and reso-
lution signal ’ is the release of free extracellular 
adenosine, generated in response to meta-
bolic stress and cell damage in renal ischemia 
or infl ammation. Adenosine A 2A receptors 
(A 2A Rs) are expressed across multiple cell 
lineages  in vivo , including endothelium, epi-
thelium, and multiple leukocyte subsets. 
Ligation of leukocyte A 2A R is associated with 
the opposition of infl ammatory activation; 
hence the adenosine – receptor system can be 
viewed as an elegant endogenous feedback 
system opposing persisting and injurious 
immune activation with promotion of the 
switch to a resolution phenotype. 
 Garcia  et al. 2 (this issue) present work 
detailing the impact of pharmacological 
A 2A R agonism and antagonism on the 
outcome of established proteinuric anti-
glomerular basement membrane (anti-
GBM) nephritis with drug treatment 
commenced 14 days aft er disease initia-
tion. Th e data presented build on their 
previous work showing that A 2A R ago-
nism from the time of disease initiation 
reduced disease severity. 3 Th e initiation of 
treatment in established disease used in 
the current study off ers a better analogy 
to the typical presentation and treatment 
of patients with rapidly progressive 
glomerulonephritis and enhances the 
translational importance of the fi ndings. 
 Garcia  et al. 2 report that the administra-
tion of the A 2A R agonist CGS 21680 has a 
prompt and sustained impact in lessening 
proteinuria and prevents progressive eleva-
tion in serum creatinine. CGS 21680-
treated animals exhibited reduced disease 
severity with a remarkable reduction in 
glomerular macrophage infi ltration associ-
ated with reduced levels of the chemokine 
CCL22 as well as reduced osteopontin, 
thrombospondin, and transforming growth 
factor-  mRNA levels. Notably, in kidneys 
treated with the agonist for 6 days, there 
was a reversal of established fi brosis with 
reduced expression of collagens III and IV 
and reduced interstitial myofibroblast 
accumulation. In contrast, A 2A R antago-
nism worsened disease outcome. 
 Th e mechanistic importance of macro-
phage recruitment in mediating tissue 
injury and subsequent fi brosis in experi-
mental models of renal disease that includes 
anti-GBM nephritis is well recognized, as 
is its contribution to progression of human 
renal disease. Th us it seems likely that the 
marked reduction in macrophage infi ltra-
tion evident in CGS 21680-treated animals 
is of major significance. However, the 
diverse expression profi le of the A 2A R  in 
vivo complicates definitive conclusions 
regarding the key cellular target of CGS 
21680 in mediating the protected pheno-
type reported, and it thus remains possible 
that reduced macrophage infi ltration is an 
epiphenomenon refl ecting reduced tissue 
injury mediated by alternative, possibly 
multiple pathways. In order to draw defi n-
itive conclusions regarding the relative con-
tributions of leukocyte and macrophage 
A 2A R activation to disease phenotype, 
studies involving bone marrow transplan-
tation or cell lineage-restricted A 2A R acti-
vation or deletion will be necessary. 
 THE IMPACT OF A 2A R ACTIVATION ON 
OUTCOME IN EXPERIMENTAL 
INFLAMMATION 
 Th e generation of A 2A R knockout mice 
and the development of pharmacological 
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A 2A R agonists and antagonists have per-
mitted exploration of the infl uence of 
A 2A R activation and blockade on outcome 
in diverse experimental models of infl am-
mation (reviewed by Hasko and Pacher 4 ). 
A 2A R agonism ameliorates classical chron-
ic infl ammatory conditions such as asthma, 
autoimmune hepatitis, and infl ammatory 
bowel disease, and acute infl ammation in 
ischemia – reperfusion injury of the heart, 
lung, and liver. Macrophages express A 2A R, 
and an extensive literature documents the 
impact of pharmacological A 2A R activa-
tion on classical activation  in vitro and 
 in vivo (reviewed by Hasko  et al. 5 ). Inter-
estingly, Garcia  et al. 2 indicate that A 2A R 
agonism markedly prevents macrophage 
accumulation at the day 20 time point, 
with limi ted alteration in the ratio between 
markers of M1 and M2 macrophage phe-
notype. It is suggested that reduced CCL22 
expression is key to the diminished macro-
phage accumulation, but it is also possible 
that reduced macrophage proliferation 
in situ , or indeed increased emigration 
to regional lymphoid structures or death 
 in situ , may also be involved. 
 A 2A R agonism has proved effi  cacious in 
models of acute kidney injury and pro-
gressive anti-GBM nephritis and diabetic 
nephropathy. 3,6,7 While reduced macro-
phage infi ltration has oft en been noted in 
conjunction with these protected pheno-
types, it is noteworthy that macrophage 
numbers were signifi cantly reduced by 
A 2A R agonism without any beneficial 
eff ect on renal scarring in the unilateral 
ureteric obstruction model. 8 Highlighting 
the pleiotropic renal eff ects of adenosine, 
A 2A R agonists and antagonists have been 
reported to modulate both renal macro-
phage number and phenotype, neutrophil 
recruitment 7 and tubuloglomerular feed-
back, 9 while  in vitro evidence suggests that 
A 2A R agonists may help preserve podo-
cyte structure and function in response to 
toxic insults. 10 Accordingly, interventions 
with A 2A R-targeting agents may be infl u-
encing renal outcome via alterations of 
immune-cell number and phenotype, 
direct actions on parenchymal cells, or 
alterations of systemic and regional hemo-
dynamics (summarized in  Figure 1 ), with 
the relative importance of each uncertain, 
and potentially varying between experi-
mental models. 
 IMMUNE MODULATION AS A 
THERAPEUTIC GOAL 
 Although macrophages are important 
eff ectors of renal injury, there is increas-
ing experimental evidence demonstrating 
their role in facilitating the successful res-
olution of tissue injury in the kidney 11 as 
well as the heart and liver. 12,13 Conversely, 
depletion of macrophage populations 
during tissue repair impedes reparative re-
sponses and the resolution of fi brosis. 11,12 
Th is has implications for novel treatments 
such as A 2A R agonists that may markedly 
reduce macrophage numbers in diseased 
tissues, as they may also act to limit the 
ability of macrophage populations to sub-
sequently eff ect optimal tissue repair. 
 Recent work by Lee  et al. demonstrates 
a macrophage  ‘ phenotypic switch ’ to M2 
polarization as a facultative step in the res-
toration of tissue integrity after renal 
ischemia – reperfusion injury. 14 Th is pat-
tern echoes the albeit moderate alteration 
in M1 / M2 macrophage marker profile 
induced by A 2A R activation that is 
reported by Garcia  et al. , 2 raising the 
intriguing possibility that such a switch (or 
its failure) is of particular importance in 
determining whether an infl ammatory 
insult persists or resolves. M1 activated 
macrophages  constitute a major line of 
innate immune defense against pathogens, 
and it is pertinent that pharmacological 
inactivation of A 2A R improves outcome 
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 Figure 1  |  Schematic diagram illustrating the diverse reported cellular targets of 
pharmacological A 2A R activation in the immune system and the kidney that may be relevant 
to outcome in inflammatory renal disease. Blue arrows indicate documented anti-inflammatory 
or pro-cell-survival actions of A 2A R activation. The red arrow indicates the positive impact of 
thrombospondin-1 (TSP-1) on the levels of bioactive transforming growth factor-  (TGF-  ). Black 
lines indicate effects of A 2A R agonism in anti–glomerular basement membrane disease as reported 
by Garcia  et al. 2 NK, natural killer; TIMP-1, tissue inhibitor of metallproteinase-1. 
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aft er experimental polymicrobial sepsis. 15 
Accordingly, it will be important to deter-
mine whether A 2A R agonists exert a con-
verse effect on outcome after sepsis if 
translational use is contemplated. It is 
striking that A 2A R activation remains ben-
efi cial even in a focus of acutely infl amed 
renal tissue, indicating that the A 2A recep-
tor system remains incompletely saturated 
even in an environment with presumably 
high levels of endogenous free adeno sine. 
Whether additional combinatorial selec-
tive activation of other adenosine receptor 
family proteins would confer addi tional 
benefits may be the subject of future 
investigation. 
 THE IMPORTANCE OF TIMING: IS THERE 
A WINDOW OF THERAPEUTIC 
OPPORTUNITY? 
 Before the current study, attempts to 
modify the course of experimental 
glome rular disease in rats using A 2A R 
activation administered drug treatment 
from the point of initial renal insult (ad-
ministration of nephrotoxic serum or 
initiation of diabetes). In each case this 
treatment largely aborted the develop-
ment of the histological and phenotypic 
markers of disease. 3,6 Almost invariably, 
the clinical presentation of glomerular 
disease occurs some time aft er the fi rst 
immunological and subsequent histolog-
ical abnormality has occurred. It remains 
unknown whether early intervention 
with a limited period of A 2A R agonism 
will be suffi  cient to initiate eff ective and 
sustained anti-infl ammatory program-
ming and tissue repair or whether pro-
longed administration will be necessary 
to prevent or retard disease progression. 
 Garcia  et al. 2 show that, at least at the 
time point studied, the development of 
renal fi brosis (as indicated by collagen III 
and IV deposition) is a dynamic process, 
which can be either opposed or potentiated 
by activation or blockade of the A 2A R sys-
tem, respectively. Th e documented changes 
in mRNA expression of transforming 
growth factor-  and thrombospondin 
(a transforming growth factor-  activator) 
as well as the ratio of MMP2 to TIMP-1 
provide a putative mechanism to promote 
increased matrix turnover with a net reduc-
tion in matrix deposition. Evidence from 
the carbon tetrachloride model of murine 
hepatic fi brosis indicates that macrophages 
are essential eff ector cells in the resolution 
of liver fi brosis and that collagen resorption 
remains possible aft er a 12-week adminis-
tration of the profi brotic agent. 12 Whether 
there is a therapeutic window beyond 
which renal fi brosis becomes irreversible 
remains uncertain, and establishing this 
will require further studies. 
 An additional consideration of rele-
vance to both the interpretation of exper-
imental A 2A R activation and the potential 
translational application of these agents 
relates to the impact of these agents on 
systemic blood pressure. Th e rapid reduc-
tion in proteinuria within 48  h of the 
commencing of CGS 21680 would sup-
port blood pressure reduction as account-
ing for at least a component of the 
reduced protein excretion. Th ese hemo-
dynamic eff ects have limited the clinical 
applications of A 2A R agonists in myocar-
dial perfusion imaging and may call for 
innovative pharmacological solutions 
such as the generation of prodrugs that 
are specifi cally activated at sites of active 
infl ammation. 16 
 CONCLUSION 
 Th e ultimate goal of the nephrologist is 
the safe induction of a complete and last-
ing remission of renal disease. Th e emerg-
ing fi eld of regenerative medicine has 
added to this already daunting challenge 
the even more ambitious aim of restor-
ing structure and function to the scarred 
failing kidney. Th is target remains distant 
and requires further expansion of our in-
complete knowledge of the initiating and 
perpetuating insults that account for the 
diverse path o logies underlying progres-
sive disease, which probably encompass 
both the adaptive and the innate arms 
of the immune response. Th erapies tar-
geting both macrophage number and 
phenotype as a  ‘ common eff ector ’ path-
way of renal damage, conserved across 
many of these pathologies, represent an 
attractive goal. It may be that A 2A R ago-
nists could form a future component of 
a mechanistically targeted combination 
therapy, in association with tolerogenic 
stimuli or targeted depletion of plasma 
cells or injurious lymphocyte subsets. 
Th e study by Garcia  et al. 2 gives cause for 
optimism regarding the potential role of 
A 2A R agonism in the treatment of renal 
disease, and a mandate for further trans-
lational work. 
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